MetLife Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

MetLife Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$717K	Buy	51,587 +1,933	+4%	+$27.2K	﹤0.01%	1573
2025 Q4	$600K	Buy	49,654 +6,725	+16%	+$91.3K	﹤0.01%	1707
2025 Q3	$583K	Hold	42,929	–	–	﹤0.01%	1730
2025 Q2	$275K	Buy	+42,929	New	+$209K	﹤0.01%	2008
2024 Q2	–	Sell	-13,768	Closed	-$39.1K	–	2881
2024 Q1	$39.1K	Sell	13,768 -12,944	-48%	-$169K	﹤0.01%	2739
2023 Q4	$393K	Hold	26,712	–	–	﹤0.01%	1828
2023 Q3	$489K	Hold	26,712	–	–	﹤0.01%	1654
2023 Q2	$576K	Hold	26,712	–	–	﹤0.01%	1597
2023 Q1	$784K	Hold	26,712	–	–	0.01%	1363
2022 Q4	$987K	Buy	26,712 +7,251	+37%	+$257K	0.01%	1219
2022 Q3	$548K	Buy	19,461 +12,676	+187%	+$316K	﹤0.01%	1576
2022 Q2	$131K	Hold	6,785	–	–	﹤0.01%	2579
2022 Q1	$87.2K	Buy	+6,785	New	+$153K	﹤0.01%	2638

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

MetLife Investment Management's AMLX Position: Q1 2026 in Review

MetLife Investment Management increased its Amylyx Pharmaceuticals (AMLX) stake by 3.9% in Q1 2026, buying an estimated $27.2K and bringing the position to 51,587 shares worth $717K. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

MetLife Investment Management first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $987K in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

MetLife Investment Management held 51,587 shares of Amylyx Pharmaceuticals worth $717K as of Q1 2026.
MetLife Investment Management bought 1,933 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $27.2K.
Amylyx Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1573 holding.
MetLife Investment Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
MetLife Investment Management's Amylyx Pharmaceuticals position peaked at $987K in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.